Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors

NCT01081808 is registered in ClinicalTrials.gov with Roger Williams Medical Center as lead sponsor.

NCT NCT01081808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors
Lead sponsor
Roger Williams Medical Center
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2009
Completion date
February 28, 2015
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, neoplasms, solid tumors, tumors